Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds.
Intellia Therapeutics Inc. (NTLA)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | ARK Investment Management Catherine D. Wood | 13,011,015 | $92,508,319 | +4% | 0.93% |
| 2. | Citadel Investment Group Ken Griffin | 2,757,568 | $19,606,308 | +11% | 0% |
| 3. | Contrarius Investment Management Stephen Mildenhall | 2,021,040 | $14,369,594 | +100% | 0.98% |
| 4. | Casdin Capital Eli Casdin | 2,000,000 | $14,220,000 | 1.16% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 1,982,317 | $14,094,274 | -1% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.50 | 4,250 | $65,875.00 | 7,500 | 2019-03-06 | Filing | |
| $16.00 | 3,250 | $52,000.00 | 3,250 | 2019-03-06 | Filing | |
| $18.00 | 58,534 | $1,053,612.00 | 2,662,180 | 2016-05-11 | Filing | |
| $18.00 | 191,466 | $3,446,388.00 | 2,603,646 | 2016-05-11 | Filing | |
| $18.00 | 300,000 | $5,400,000.00 | 790,527 | 2016-05-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.50 | 265 | $2,252.50 | 19,203 | 2025-04-29 | Filing | |
| $8.99 | 679 | $6,104.21 | 95,369 | 2025-03-04 | Filing | |
| $8.99 | 2,572 | $23,122.28 | 111,925 | 2025-03-04 | Filing | |
| $9.97 | 265 | $2,642.05 | 19,468 | 2025-01-29 | Filing | |
| $12.18 | 1,372 | $16,710.96 | 45,640 | 2025-01-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 10,752,031 | $76,446,941 | 0% | |
| 2. | 10,556,190 | $75,054,514 | 0% | |
| 3. | 4,510,261 | $32,067,956 | 0% | |
| 4. | 3,801,695 | $27,030,056 | 0% | |
| 5. | 3,779,424 | $26,871,705 | 0.01% |
News See All
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is among the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright have reaffirmed a Buy rating on Intellia Therapeutics, Inc.
10 Best NASDAQ Stocks Under $50 to Buy
In this era where everyone is striving for the best, whether it be something in daily life or technology, the stock market is no exception.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2025 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia' First Quarter 2025 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
10 Stocks Under $10 that Will Triple
As we delve into the discussion on stocks that will triple, we must shed light on the U.S.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2024 Earnings Call Transcript
Operator: Good morning, and welcome to Intellia Therapeutics' Fourth Quarter and Full-Year 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.
Cathie Wood's Stock Portfolio: 2025 Stock Picks
Cathie Wood is one of Wall Street's most contentious figures.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...